Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
13Customers
4Debt Items
20Related Chains
Source-Backed Evidence Depth
Revolution Medicines, Inc. (RVMD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
23Total relationships
3Distinct source URLs
12High confidence
0.791Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Revolution Medicines, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
92%
We rely on and will continue to rely on contract manufacturing organizations (CMOs) for both drug substance and drug product.
CMOS
CMOS
90%
Our agreements with CMOs may obligate them to develop and qualify upstream and downstream processes, develop drug product process, validate (and, in some case
Reciprocal relationship from RPRX graph: STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. W…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from SNYN…
Reciprocal relationship from TNGX graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from TNGX graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from TNGX g…
Revolution Medicines, Inc. Customers
Ticker
Name
Confidence
Evidence
ROYALTY-PHARMA-INVESTMENTS-2019-ICAV
ROYALTY-PHARMA-INVESTMENTS-2019-ICAV
92%
Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered revenue payments with respect to worldwide net product sales of (i) RMC-6236 Products…
Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered revenue payments with respect to worldwide net product sales of (i) RMC-6236 Products…
Reciprocal relationship from RPRX graph: In June 2025, Royalty Pharma (the “Company”) and Revolution Medicines announced a $2 billion funding agreement, consisting of a synthetic royalty of up to $1.…
Reciprocal relationship from ERAS graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS g…
SNYNF
Sanofi
85%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMD graph: ement was terminated in June 2023, and Sanofi has no further reimbursement obligations following this termination. T…
Reciprocal relationship from SLXN graph: not entered into binding agreements with any such manufacturers to support commercialization. We do not currently have the experience or ability to produce pr…
SNYNF
Sanofi
72%
ement was terminated in June 2023, and Sanofi has no further reimbursement obligations following this termination. To date, we have devoted substantially all of our resources to organizing and staffi…
Reciprocal relationship from TNGX graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from TNGX graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from TNGX g…
AETHON-THERAPEUTICS-INC
AETHON-THERAPEUTICS-INC
62%
Item 8 of this Annual Report on Form 10-K. Aethon Collaboration In March 2024, we entered into a collaboration agreement with Aethon Therapeutics, Inc. (Aethon) pursuant to which Aethon is conducting…
CM-LIFE-SCIENCES-III-INC
CM-LIFE-SCIENCES-III-INC
62%
ted- average remaining useful life (in thousands) (in years) In-process research and development — RAS Programs $ 55,800 $ — $ 55,800 n/a Developed technology — tri-complex platform 7,480 ( 7,480 ) —…
COMPANY-LLC
COMPANY-LLC
62%
ific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable advance payments for goods or services to be received in future per…
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC
62%
, the associated royalty rates would be lower for each of the net sales tiers. Additionally, the Royalty Purchase Agreement provides for an upward adjustment to the Royalty Payment rates in the years…
USA-LLC
USA-LLC
62%
c tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable advance payments for goods or services to be received in future period…
Revolution Medicines, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RVMD-DEBT
Debt stack $437.3M
90%
Market cache reports total debt of $437.3M.
RVMD-DEBT-41654
Debt
90%
debt detail from 424B5 2026-04-13.
RVMD-DEBT-12300
Warrants outstanding: 95422000
90%
xbrl warrant detail from xbrl 2025-12-31.
RVMD-DEBT-12301
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Revolution Medicines, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Revolution Medicines, Inc..
Revolution Medicines, Inc. Ownership
Holder
Name
Confidence
Evidence
RVMD-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 520 tracked holders.
Revolution Medicines, Inc. Extended Supply Chain Network
